The Complete Blood Count Advanced (CBC Advanced) test provides a comprehensive assessment of blood health by measuring various parameters of red blood cells, white blood cells, and platelets. It goes beyond the standard CBC by including additional markers like reticulocyte count, immature granulocyte count, and platelet indices, offering a deeper understanding of blood cell production, function, and potential abnormalities. This advanced test is valuable in diagnosing a wide range of conditions, including anemia, infections, blood clotting disorders, and certain types of cancer.

REVIEW OF PERIPHERAL BLOOD SMEAR IS COMMONLY USED TO IDENTIFY ABNORMALITIES. THIS IS SPECIALLY INDICATED IN ANEMIAS THAT DO NOT RESPOND TO THERAPY, ANEMIAS WITHOUT APPARENT CAUSE OR IF HEMOLYSIS, BONE MARROW FIBROSIS OR TUMOR INVASION IS SUSPECTED. IDENTIFICATION OF FRAGMENTED RBC, SPHEROCYTES, SICKLE CELLS, INTRACELLULAR INCLUSIONS OR PARASITES CAN ONLY BE MADE BY EXAMINING THE PERIPHERAL SMEAR.

BCR-ABL IS A FUSION GENE FORMED BY THE REARRANGEMENT OF BREAKPOINT CLUSTER REGION (BCR) ON CHROMOSOME 22 WITH THE ABL PROTOONCOGENE ON CHROMOSOME 9 LEADING TO THE FORMATION OF PHILADELPHIA CHROMOSOME. THIS REARRANGEMENT IS SEEN IN ALMOST 95% PATIENTS WITH CML. THE QUANTITATIVE ASSAY HELPS IN THE MANAGEMENT OF THE DISEASE AND MONITORS EFFECT OF THERAPY.

THIS ASSAY IS USED FOR MONITORING POST TRANSPLANT ENGRAFTMENT OF DONOR DERIVED MYELOID CELLS; MONITORING AUTOLOGOUS MYELOID CELL RECOVERY IN HSCT PERFORMED FOR MYELOID LEUKEMIAS; MONITORING IMMUNE RECOSTITUTION POST HSCT.

THE (8;21) TRANSLOCATION IDENTIFIES A SUBGROUP OF ACUTE MYELOID LEUKEMIA (AML) WITH A RELATIVELY GOOD PROGNOSIS WHICH MAY REQUIRE A DIFFERENT TREATMENT. IT IS USUALLY ASSOCIATED WITH AML SUBTYPE M2. DETECTION OF T(8;21) HAS DIAGNOSTIC, PROGNOSTIC & THERAPEUTIC IMPLICATIONS FOR THE PATIENT.

THIS PANEL MAY BE USED FOR RISK STRATIFICATION IN AML / ALL.